Putting the theory of personalised medicine into practice

Treatment of ALK+ lung cancer with crizotinib, Profile 1007

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

Trametinib and dabrafenib combination therapy against metastatic melanoma

Personalised cancer medicine and research: Today’s best practice

Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study

Phase I study examining PI 3 kinase inhibitor for various tumours

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer

Too few women being offered breast-conserving treatment?

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF